Randomized, Double-blind, Parallel-group, Placebo-controlled, 52-week, Phase IIb Study to Assess Efficacy and Safety of GLPG1690 on Top of Pirfenidone or Nintedanib in Patients with Idiopathic Pulmonary Fibrosis (IPF)
|Effective start/end date||9/19/18 → 9/18/21|
- GALAPAGOS NV
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.